Article
Molecular characterization of canine SHP2 mutants and anti-tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma.
Veterinary and comparative oncology - 1 Mar 2022
Tani Hiroyuki, Miyamoto Ryo, Nagashima Tomokazu, Michishita Masaki, Tamura Kyoichi, Bonkobara Makoto
Abstract excerpt
Canine histiocytic sarcoma (HS) is an aggressive and highly metastatic neoplasm. Mutations in src homology 2 domain-containing phosphatase 2 (SHP2; encoded by PTPN11), which recently have been identified in canine HS tumour cells, could be attractive therapeutic targets for SHP099, an allosteric inhibitor of SHP2. Here, molecular characteristics of wild-type SHP2 and four SHP2 mutants (p.Ala72Gly, p.Glu76Gln,...
Topics
- Animals
- Disease Models, Animal
- Dog Diseases
- Dogs
- Heterografts
- Histiocytic Sarcoma
- Mice
- Mutation
- Neoplasms
- Piperidines
- Pyrimidines